ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing ciclosporin (CsA) 0.1% eye drops on the MOH List of Subsidised Drugs for treating severe vernal keratoconjunctivitis due to the uncertain clinical and cost effectiveness compared with current standard of care.

Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis (19 December 2022) PES Ciclosporin eye drops for treating severe vernal keratoconjunctivitis (19 December 2022)